Status:

COMPLETED

Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation

Lead Sponsor:

University Hospital Freiburg

Conditions:

Secondary Hypothyroidism

Hypopituitarism

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to determine whether a body weight adjusted dose of thyroxin is superior to treatment guided by laboratory results of thyroxin hormones in patients with central hypothyroi...

Detailed Description

Backround: A normal thyroid function is critical for metabolism, well-being and cognitive function. It is now well accepted that primary subclinical hypothyroidism, characterized by normal circulating...

Eligibility Criteria

Inclusion

  • hypopituitarism of at least 3 axes (TSH plus gonadotropin, somatotropin, corticotropin or ADH deficiency)
  • termination of surgical or radiation treatment of pituitary tumors at least six month before study entry
  • BMI of 20 - 39.9 kg/m2
  • non-smoking status.

Exclusion

  • history of cardiovascular or pulmonary diseases
  • current thyroxin dosage \> 1.6 µg/kg bw
  • pregnancy
  • epilepsy
  • cerebrovascular diseases
  • nodular goiter

Key Trial Info

Start Date :

February 1 2004

Trial Type :

INTERVENTIONAL

End Date :

April 1 2007

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT00360074

Start Date

February 1 2004

End Date

April 1 2007

Last Update

June 9 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Freiburg, Department of Medicine

Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79104

Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation | DecenTrialz